Rare and Orphan Disease Trials

Leveraging Patient Registries for Rare Disease Clinical Research

Posted on digi By digi

One of the most critical challenges in rare disease clinical research is identifying and enrolling eligible participants. Given the low prevalence and heterogeneous presentation of many rare disorders, traditional recruitment approaches often fall short. Patient registries—organized databases collecting clinical, genetic, and demographic information—offer a strategic advantage by facilitating identification, characterization, and engagement of patients who meet protocol criteria.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Using Clinical Trial Simulation Models for Rare Diseases

Posted on digi By digi

Designing clinical trials for rare diseases is uniquely challenging. Sponsors must optimize protocols to work within constraints like small sample sizes, heterogenous patient populations, and ethical limitations. Clinical trial simulation models are increasingly being adopted as powerful tools to navigate this complexity. By using mathematical models to simulate trial conduct, sponsors can anticipate outcomes, refine protocols, and increase their likelihood of regulatory and scientific success.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Bayesian Trial Designs for Small Sample Rare Disease Studies

Posted on digi By digi

Traditional frequentist statistical methods often fall short in rare disease clinical trials due to small sample sizes, high variability, and ethical concerns about placebo use. Bayesian designs offer a flexible, data-efficient alternative that is particularly suited for orphan indications. By incorporating prior knowledge and updating probabilities as new data emerge, Bayesian methods enhance trial adaptability, decision-making, and statistical power in settings where patient numbers are limited.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Platform Trial Approaches in Rare Disease Research

Posted on digi By digi

In the realm of rare disease research, traditional trial structures often prove inefficient. Small patient populations, high clinical heterogeneity, and the urgent need for accelerated drug development demand innovative study designs. Platform trials—also known as master protocol trials—are increasingly becoming a game-changer. They allow the simultaneous evaluation of multiple treatments within a single, unified infrastructure, significantly reducing costs, timelines, and patient burden.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Designing Single-Arm Studies for Regulatory Acceptance

Posted on digi By digi

In rare and ultra-rare disease drug development, the small number of eligible patients often precludes the use of traditional randomized controlled trials (RCTs). In these settings, single-arm studies—where all enrolled patients receive the investigational therapy—can serve as a scientifically and ethically justifiable alternative. Regulatory bodies including the FDA, EMA, and PMDA recognize the validity of single-arm designs when supported by robust historical data and clearly defined endpoints.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Handling Missing Data in Rare Disease Clinical Trials

Posted on digi By digi

In rare and ultra-rare disease clinical trials, each data point holds immense value. The limited pool of eligible participants means that even a small proportion of missing data can significantly impact statistical power, data interpretability, and regulatory acceptance. Missing data may arise from various sources including patient dropouts, protocol deviations, missed visits, or uncollected endpoint measurements.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Selecting Appropriate Control Groups in Rare Disease Studies

Posted on digi By digi

In clinical research, the control group serves as a critical comparator to evaluate the safety and efficacy of a new treatment. In the context of rare and ultra-rare diseases, however, selecting an appropriate control group presents unique challenges. With patient populations often numbering in the tens or low hundreds globally, traditional randomized controlled trial (RCT) designs may not be feasible or ethical.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Surrogate Endpoint Validation in Orphan Drug Development

Posted on digi By digi

In the world of rare disease clinical research, traditional clinical endpoints—such as survival or long-term functional improvement—can be impractical due to small patient populations, disease heterogeneity, and long progression timelines. This is where surrogate endpoints come in. These are intermediate or substitute measures used to predict the effect of a treatment on a true clinical outcome.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Multi-Arm, Multi-Stage Designs for Small Patient Populations

Posted on digi By digi

Rare disease clinical trials face persistent challenges—limited patient populations, ethical constraints around control arms, and high uncertainty in treatment effects. In such scenarios, traditional parallel-group designs can be inefficient, slow, and unfeasible. This is where Multi-Arm, Multi-Stage (MAMS) designs provide a significant advantage.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology

Hybrid Clinical Trial Models for Rare Disease Research

Posted on digi By digi

Rare disease trials often face significant logistical hurdles—patients may live far from trial centers, travel burdens are high, and access to specialized sites is limited. To address these challenges, hybrid clinical trial models are gaining traction. These designs combine the best of both worlds: traditional site visits for critical assessments and decentralized methods (e.g., remote monitoring, telehealth) for improved flexibility and reach.
Click to read the full article.

Rare and Orphan Disease Trials, Trial Design & Methodology